StockData
Maze Therapeutics, Inc. logo

Maze Therapeutics, Inc. (MAZE) stock

MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$32.87−1.03 (-3.04%)

Close on Nov 17, 2026Market cap $1.83BP/E –Yield –

Maze Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Maze Therapeutics's price to book ratio was 4.5× on Nov 11, 2026, against 4.8× a year earlier.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20264.5×−0.8
2025Dec 31, 20255.2×–

More Maze Therapeutics figures

See a number that looks wrong?